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Abstract  
INTRODUCTION: Type 1 diabetes mellitus (T1DM) is one of the most common chronic diseases in children that 
may be complicated by micro or macrovascular complications. Measurement of the carotid intima-media thickness 
(CIMT) allows the early detection of atherosclerotic alterations of blood vessels that may complicate T1DM. 
SUBJECTS AND METHODS: This study is a case-control study. Participants were classified into two groups. The 
first group included 40 children with T1DM and the second group included 30 matched healthy controls. The 
studied cases were recruited from Endocrinology and Diabetology Unit, Pediatric Hospital, Ain Shams University. 
Serum apelin, cholesterol, TG, LDL were measured for every case. Also, albumin level was analyzed in urine. 
Measurement of the carotid intima-media thickness (CIMT) was done for all cases. 
RESULTS: Comparison between T1DM patients and controls revealed that serum apelin, cholesterol, TG, LDL 
and albuminuria were significantly increased in cases compared to controls. Significant positive correlations were 
detected between HbA1C, albuminuria and lipid profile with apelin in the diabetic group (p < 0.05). CIMT has 
significant positive correlation with serum apelin levels (r = 0.36, p = 0.05). Also, this study found positive 
correlations between CIMT and some variables as LDL, SBP z-score and duration of the illness. 
CONCLUSION: Increased levels of serum apelin in T1DM patients may be considered as predicting factor for the 
ongoing development of vascular sequels. This study highlighted the possible validity of apelin assay as an early 
predictor of atherosclerosis in T1DM children. Evaluating CIMT in these patients is of at most important for early 
detection of subclinical atherosclerosis. 
 
 
 
 
Introduction 
 
Type 1 diabetes mellitus (T1DM) is a 
multifactorial health problem worldwide. It is one of the 
most common chronic diseases in children that may 
be complicated by micro or macrovascular 
complications [1]. Endothelial dysfunction and 
subclinical organ damage indices, such as greater 
Carotid Intima-Media Thickness (CIMT) and arterial 
atherosclerotic changes, reﬂecting higher 
cardiovascular diseases (CVD) risk in adulthood, are 
increased with hyperglycemia, hypertension, high LDL 
and TG concentrations, insulin resistance, increased 
BMI, proinﬂammatory status and disturbances in 
adipocytokines [2]. The direct impedance of 
adipokines on the endothelium needs further 
investigations. Endothelial dysfunction is considered 
the early stage of atherosclerotic changes that may 
affect blood vessels in T1DM [3]. It is characterised by 
abnormalities in the lumen and endothelium of the 
blood vessels, resulting in vasodilatation response. 
These changes in vascular endothelium result in 
increased secretion of inflammatory cytokines that 
augment adhesion of cellular molecules and other 
biologically active substances and finally lead to a 
proinflammatory and prothrombotic state [4]. These 
mechanisms represent an important step in the 
development of the initial atherosclerotic changes and 
subsequent complications in diabetic children [5]. 
Measurement of the carotid intima-media thickness 
(CIMT) allows the early detection of atherosclerotic 
alterations of blood vessels. It is considered a strong 
predictor of vascular abnormalities in high-risk 
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individuals, such as those with T1DM [6]. 
Measurement of the intima-media thickness of the 
large arteries, especially the carotids, has considered 
as the method of choice for detecting the anatomical 
extent of arterial wall deterioration and for assessing 
cardiovascular risk [7]. Several investigators have 
recommended the clinical use of this technique for 
detecting subclinical (asymptomatic) atherosclerosis 
and for identifying subjects at high-risk. 
Apelin is one of the adipokines that is 
secreted from white adipose tissue and has various 
functions as insulin sensitivity. It has an important role 
in diabetes mellitus. Furthermore, its concentration is 
changed according to insulin resistance. It has been 
shown that apelin has a crucial role in energy 
metabolism and pathogenesis of diabetes mellitus 
because white adipose tissue that secretes apelin 
acts as an endocrine organ [8]. 
Apelin had been discovered by Tatemoto et 
al., in 1998 [9]. They suggested that it is the 
endogenous ligand for angiotensin II protein J (APJ) 
receptor [10]. Apelin and its receptor APJ are 
expressed in several tissues like heart, lung, stomach 
and skeletal muscles. In the past few years, it has 
been found the possible roles played by apelin in 
human physiology, It is considered as regulating 
peptide of cardiovascular, hypothalamus-hypophysis, 
gastrointestinal and immune systems [11]. Scientists 
stated that apelin might be a risk indicator in young 
children prone to atherosclerosis and type 2 diabetes 
[12]. Moreover, some previous studies found apelin as 
a novel biomarker for predicting diabetes especially 
T1DM [13]. In healthy individuals, the level of apelin 
depends on the nutritional state. It was reduced in 
fasting and increased by feeding, while in diabetic 
patients and impaired glucose tolerance it may 
increase due to insulin resistance [14]. Insulin 
increased the expression of apelin in adipocytes [15]. 
This study aims to analyse the role of the 
adipokine apelin in the pathogenesis and 
complications of type I diabetes mellitus in children. 
Also, we aimed to clarify the relation between serum 
apelin and lipid concentrations and to verify the 
presence of CIMT and initial structural atherosclerotic 
changes in children with Type 1 diabetes mellitus 
(T1DM). 
 
 
Subjects and Methods 
 
This study is a case-control study. 
Participants were classified into two groups. The first 
group included 40 children with T1DM, their mean age 
was 9.15 ± 3.64 years, and the mean duration of 
disease was 4.5 years. The second group included 30 
matched healthy controls, of same age group. Cases 
with T1DM were classified into two subgroups 
according to HbA1c, group I with HbA1C of 8% or less 
(well-controlled T1DM) and group II with HbA1c 
greater than 8% (poorly controlled T1DM). 
The studied cases were recruited from 
Endocrinology and Diabetology Unit, Pediatric 
Hospital, Ain Shams University. Healthy children were 
peers of diabetic patients and from local schools. 
Cases with the chronic or inflammatory disease, 
cases which were on medications or hormones (other 
than insulin), cases with known renal disease and 
systemic disease and acute infection at the time of 
testing were excluded from the study. The study was 
approved by the local ethics committee of National 
Research centre, and written informed consent was 
obtained from both parents of every participant. 
All participants were subjected to: 
- Full history with special emphasis on the 
onset of diabetes. 
- Clinical examination and anthropometric 
measurements including Height (in centimetres) using 
Harpenden stadiometer and Weight (in kilograms) 
using an electronic weight scale.  
- calculation of BMI: weight in kg/(height in 
meters)
2
.  
- Weight for age, height for age and BMI Z -
score were determined using the new WHO reference 
[16].  
- Measuring blood pressure (BP) by a 
sphygmomanometer. 
Venous blood samples (3 ml) were taken from 
each child participating in the study and divided into 
two parts: the first part was added to a tube containing 
EDTA for glycosylated haemoglobin determination by 
cation-exchange resin and the second part was put in 
a serum separator tube. The separated serum was 
stored at – 20
0
C for determination of Apelin, fasting 
blood sugar, total cholesterol, and triglyceride (TG), 
HDL and LDL. Fasting blood glucose level was 
performed on automated clinical chemistry analyser 
(Olympus AU400). Total cholesterol, triglyceride and 
HDL were determined using colourimetric techniques 
on Synchron Cx7 (Beckman Instruments Inc., 
California, USA). LDL cholesterol was measured by 
Friedwald formula [17]. For random urinary albumin 
measurement, an early morning mid-stream specimen 
was used. The cloudy samples were centrifuged 
before use, and the clear supernatant was stored at -
20°C until analysis. Albumin concentrations were 
measured in urine using a Minineph microalbumin kit 
based on nephelometry method on 
Mininephnephlometer (AD200) (The Binding Site, 
Birmingham, UK) [18]. We compared albumin in the 
sample against its creatinine concentration (measured 
by Jaffe reaction) on a Synchron Cx7 autoanalyser, 
and the albumin/creatinine ratio was calculated [19]. 
Serum Apelin was measured by quantitative 
commercial enzyme-linked immunosorbent assay 
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ELISA kit supplied from Elabscience Biotechnology 
Co., Ltd, Wu Han, China-Catalog No: E – EL-H0456 
(www.elabscience.com), detection range was 
between 62.5-400 pg/ml. 
Measurement of carotid intima-media 
thickness (CIMT) was performed using high-resolution 
B mode ultrasound to detect the thickness of Common 
Carotid Arteries. All of the carotid scans were done 
using carotid Doppler ultrasound scanner (Toshiba 
Ultrasonography machine [Xario], Tokyo, Japan) with 
a 10.0-MHz linear array transducer following a 
predetermined standardised scanning protocol [20].  
The data were coded, entered and processed 
by computer using Statistical Program for Social 
Science version 22 (SPSS Inc., Chicago, IL, USA). 
Quantitative variables were described in the form of 
mean and SD concerning age, BMI Z-score, systolic 
and diastolic BP Z-score, level of HbA1C, cholesterol, 
TG, and level of Apelin and qualitative variables were 
described as number and percent concerning sex 
distribution and presence of albuminuria. To compare 
quantitative parametric variables between two groups, 
Student t-test was used. Pearson correlation 
coefficient was employed to measure the strength and 
direction of the linear relationship between two 
variables. A p-value < 0.05 was considered the cut-off 
value for significance in all analyses. 
 
 
Results 
 
Subjects in this study were classified into two 
groups. The first group is cases which involve 40 
children with type I diabetes mellitus, of them 17 were 
males and 23 were females. The second group 
controls which involve 30 healthy children, of them 11 
were males, and 19 were females. No significant 
difference was found between cases and controls in 
relation to age. 
Table 1 shows a comparison of 
anthropometric and clinical parameters between 
cases and controls; there was highly significant 
difference between the two groups regarding SBP and 
DBP z-score (p < 0.01). No significant difference was 
found between the two groups as regards weight, 
height and BMI z-score. 
Table 1: Comparison of anthropometric and clinical parameters 
between cases and controls 
Variable 
Cases 
(n = 40) 
Mean ± sd 
Control 
(n = 30) 
Mean ± sd 
P 
Age (years) 9.15 ± 3.64 9.70 ± 4.38 0.63 
Weight z-score 0.61 ± 0.47 -0.42 ± 0.67 0.12 
Height z-score -0.48 ± 1.21 -0.27 ± 1.14 0.77 
Bmi z- score 0.67 ± 1.28 0.41 ± 0.83 0.52 
Sbp z-score 0.76 ± 0.44 0.16 ± 0.36 0.001* 
Dbp z-score 1.1 ± 0.49 0.41 ± 0.38 0.000* 
 
Table 2 shows a comparison of laboratory 
markers between cases and controls. Serum apelin, 
cholesterol, TG, LDL and albuminuria were 
significantly increased while HDL was significantly 
decreased in cases compared to controls. 
Table 2: Comparison of laboratory markers between cases and 
controls 
Variable 
Cases 
(n = 40) 
Mean ± sd 
Control 
(n = 30) 
Mean ± sd 
P 
Apelin (pg/ml) 1040 ± 576 741.8 ± 231.6 0.015* 
Albuminuria (mg/gm creatinine) 46.46 ± 32.08 9.83 ± 5.07 0.02* 
Cholesterol (mg/dl) 217.6 ± 44.30 139.27 ± 19.3 0.000* 
TG (mg/dl) 156.8 ± 18.94 76.53 ± 7.12 0.000* 
LDL (mg/dl) 183.32 ± 46.71 58.16 ± 13.45 0.000* 
HDL (mg/dl) 23.27 ± 5.43 46.14 ± 10.2 0.000* 
 
Table 3 shows correlations between Apelin 
and anthropometric, clinical and laboratory data in the 
Diabetic group. DBP z-score has significant positive 
correlation with apelin in diabetic group (p < 0.05). 
HbA1C, albuminuria and lipid profile of diabetic 
children had a highly significant positive correlation 
with apelin (p < 0.001). Mean CIMT in diabetic 
children was 0.5 ± 0.1 mm. 
Table 3: Correlation between Apelin and anthropometric, 
clinical and laboratory data in the Diabetic group 
variable 
Diabetic 
(N = 40) 
r p 
DBP z-score 0.292 0.02* 
HbA1C 0.441 0.001* 
Cholesterol 0.404 0.001* 
TG 0.401 0.001* 
LDL 0.402 0.001* 
CIMT 0.362 0.05* 
Albuminuria 0.887 0.000* 
 
CIMT had significant positive correlation with 
serum apelin levels as shown in figure 1 (r = 0.36, p = 
0.05). Also, this study found a positive correlation 
between CIMT and some variables as LDL, SBP z -
score and duration of the illness (p < 0.05). Also, 
Duration of diabetes was positively correlated with 
LDL (p = 0.03). HbA1C was positively correlated with 
DBP z-score and albuminuria (p < 0.05). 
0.90.80.70.60.50.4
CIMT
3000
2000
1000
0
A
pe
lin
r= 0.36         P=0.05
 
Figure 1: Correlation between serum apelin levels and CIMT 
 
We also investigated the influence of different 
clinical and laboratory variables on diabetic 
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nephropathy occurrence. It revealed that serum apelin 
and Hb1C had a significant influence on the 
appearance of diabetic nephropathy. This is 
discovered by detecting a positive correlation between 
albuminuria and serum apelin, HbAc (p < 0.05). 
 
 
Discussion 
 
Apelin is an adipokine that is secreted from 
adipocytes in different organs. It has been shown that 
serum apelin was involved in glucose homeostasis 
and also it regulates insulin secretion. In this study, 
we found that serum apelin levels are significantly 
increased in children with T1DM in comparison to 
healthy subjects, this is in agreement with previous 
studies [21] [22]. This is maybe explained by that 
apelin action on glucose metabolism is additive to 
insulin as it increases glucose uptake and transport in 
tissues [15], also it increases intestinal absorption of 
glucose [23]. All reported previous actions of apelin 
make it an anti-diabetic agent. Thus, our study 
hypothesised that increased levels of apelin in T1DM 
is a result of compensatory mechanism devoted to 
decreased insulin levels and to overcome insulin 
resistance in these patients. This study also found a 
highly significant positive correlation between serum 
apelin and HbA1c in diabetic subjects; this is in 
contrary with a previous study [22], who stated that 
serum apelin levels were negatively correlated to 
HbA1c in type 2 diabetic patients, suggesting that 
circulating apelin is associated with the better 
glycemic control. This difference may be explained by 
the fact that patients with T1DM in our study were 
treated with insulin which plays an important role in 
apelin secretion and expression. 
In this study, we found a significant influence 
of serum apelin on diastolic blood pressure, it 
increases with increased serum apelin levels, but it 
does not affect systolic blood pressure. This is in 
disagreement with a previous study [12], which 
discovered that there was not a significant influence of 
serum apelin on SBP, but there was a tendency to 
lower DBP with higher levels of serum apelin, this 
discrepancy is due to that they studied elderly 
subjects with an increased risk to develop T2DM. To 
check the further influence of serum apelin on 
vascular integrity, we studied the CIMT as a 
parameter for early atherosclerotic changes in blood 
vessels in T1DM patients. CIMT has been described 
as a mirror of the atherosclerotic burden and a 
predictor for the subsequent sequel as myocardial 
infarction and stroke [24]. From the previous 
advantages of this technique, we decided to use it as 
a gold standard for early detection of subclinical 
atherosclerosis in T1DM patients. We discovered 
positive correlations between CIMT and LDL; this 
ensures our recommendation that CIMT should be 
done for every T1DM patient for early detection of 
atherosclerosis. We found that serum apelin levels 
have a significant positive correlation with CIMT in 
T1DM. Thus, we can consider increased levels of 
serum apelin in T1DM as predicting factor for the 
further development of vascular complications of DM 
in these patients. In our study, HbA1C was positively 
correlated with DBP z-score. This may be explained 
by that increased glycemic state is associated with 
increased vasoconstriction and hypertension due to 
inflammatory state that induces oxidative stress that 
alters nitric oxide secretion and degradation and 
finally has a deleterious effect on vascular endothelial 
cells. Our results concerning hyperglycemia and 
increased blood pressure are in agreement with a 
previous study [25]. Furthermore, this study also 
clarifies the role of apelin in the occurrence of diabetic 
nephropathy. We found that serum apelin and Hb1C 
have a significant influence on the appearance of 
these complications. We discovered that serum apelin 
was associated with increased diabetic nephropathy 
which correlated with microalbuminuria. This is 
ensured by another study [26], which stated that 
apelin induce glomerular endothelial cells proliferation 
and then nephropathy so we can state that increased 
serum apelin may worsen the condition in T1DM 
through its influence on diabetic nephropathy. 
In our study, we reported that serum 
cholesterol; TG and LDL were significantly increased 
in T1DM patients than healthy subjects, but serum 
HDL was significantly decreased in T1DM patients 
than healthy subjects. From the previous results, we 
can consider children with T1DM at higher risk of 
developing premature atherosclerosis because of 
hyperlipidemia and thus, should be screened well for 
this serious complication. Also, we found significant 
positive correlations between serum apelin and serum 
cholesterol, LDL and TG in diabetic patients. In 
support of these results, other study found statistical 
differences between diabetic and non-diabetic groups 
as regards serum levels of TG and cholesterol [25]. 
Also, other study reported the same results as regards 
serum TG [13]. Few studies describe the effects of 
apelin on lipid metabolism; one of them stated that 
apelin was shown to inhibit lipolysis [27]. This was 
ensured by another study [28] that found that apelin 
increases the stability of lipid vacuoles making them 
more resistant to lipases. All these findings support 
our results that apelin is associated with increased 
serum lipids and thus can be used as a predictor of 
premature atherosclerosis in T1DM patients. 
In conclusion, increased levels of serum 
apelin in T1DM patients may be considered as 
predicting factor for the ongoing development of 
vascular sequels so measuring serum apelin in these 
patients is of benefit for early detection of disease 
complications. Premature subclinical atherosclerosis 
was documented among T1DM patients due to 
hyperlipidemia detected in these patients, so we 
recommend evaluating their CIMT for early detection 
of subclinical atherosclerosis. CIMT was correlated 
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well with dyslipidemia and serum apelin, a finding that 
highlighted the possible validity of apelin assay as an 
early predictor of atherosclerosis in T1DM children. 
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